Ischemic Heart Disease (IHD) Drugs Market to Grow with a CAGR of 4.20% through 2030
Rising Prevalence of Cardiovascular Risk Factors is expected
to drive the Global Ischemic Heart Disease (IHD) Drugs Market growth in the
forecast period, 2026-2030.
According to TechSci Research report, “Ischemic Heart Disease (IHD) Drugs - Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global
Ischemic Heart Disease (IHD) Drugs Market stood at USD 5.98 Billion in 2024 and is
anticipated to grow with a CAGR of 4.20% through 2030. The growing
prevalence of cardiovascular risk factors is a key driver for the global
Ischemic Heart Disease (IHD) drugs market. The rise in conditions like
hypertension, diabetes, obesity, and sedentary lifestyles leads to a higher
incidence of IHD, driving demand for effective treatments. These factors
contribute to the narrowing and stiffening of arteries, which increases the
likelihood of IHD. Additionally, high stress, poor dietary habits, and smoking
further contribute to the growing burden, particularly in both developed and
emerging economies.
As more people are affected by these risk factors,
there is a greater need for both preventative measures and therapeutic drugs to
manage IHD. Increased awareness and focus on cardiovascular health have
prompted more individuals to seek treatment, further escalating demand for IHD
medications. This growing market demand is driving innovation in drug
development, presenting expanded opportunities for pharmaceutical companies. Additionally,
as healthcare access improves in emerging markets, and with the rising
prevalence of these risk factors, there is a significant growth opportunity in
these regions. The combination of rising chronic disease rates and continued
advances in drug development will drive the expansion of the IHD drugs market
worldwide.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on " Global Ischemic Heart Disease (IHD) Drugs Market”
Global Ischemic Heart Disease (IHD) Drugs Market is
segmented into disease class, drug class, regional distribution, and company.
Based on Drug Class, Anti-Dyslipidemic Drugs emerged as the fastest
growing segment in the global market for Ischemic Heart Disease (IHD) Drugs in
2024.
Dyslipidemia,
characterized by elevated LDL cholesterol and low HDL cholesterol, is a
significant risk factor for ischemic heart disease (IHD). With the aging global
population and rising lifestyle-related risk factors such as poor diet and
inactivity, dyslipidemia is becoming more prevalent, increasing the demand for
medications to manage cholesterol levels. Anti-dyslipidemic drugs, particularly
statins, are well-established for lowering LDL cholesterol and preventing
cardiovascular events like heart attacks and strokes, making them essential in
IHD treatment and driving consistent market growth. Additionally, newer
therapies such as PCSK9 inhibitors and ezetimibe are gaining traction,
especially among statin-intolerant patients or those requiring more aggressive
cholesterol reduction. These advancements are contributing to the rapid
expansion of the anti-dyslipidemic drug market. Rising awareness about
cardiovascular health and the importance of cholesterol management has led to
more diagnoses and early interventions, which help prevent severe forms of IHD,
further boosting demand for these drugs. As governments, healthcare
organizations, and physicians increasingly focus on preventing cardiovascular
diseases, the recognition of dyslipidemia as a key modifiable risk factor has
further emphasized the need for anti-dyslipidemic treatments. Collectively,
these factors position the anti-dyslipidemic drugs segment as the
fastest-growing in the IHD drugs market, as both established and emerging
treatments gain wider adoption.
Based on Region, the Asia Pacific region is expected
to be fastest growing region during the forecast period in global Ischemic Heart Disease (IHD)
Drugs market. The growing prevalence of risk factors like hypertension, diabetes,
obesity, and poor diet, especially in countries such as China and India, is
leading to a higher incidence of ischemic heart disease (IHD). As these
conditions become more common, the demand for effective treatments increases.
In countries like Japan, China, and South Korea, significant demographic shifts
and aging populations are driving the rising incidence of IHD, further boosting
treatment demand. Additionally, rapid improvements in healthcare infrastructure
and access to advanced medical technologies in nations like China and India are
enhancing the diagnosis and management of IHD, supporting market growth.
Governments and private organizations in the Asia-Pacific region are making substantial
investments in healthcare, particularly in cardiovascular health programs,
which promote the use of IHD treatments. Growing awareness of cardiovascular
health and an increased focus on early detection and prevention are leading to
more IHD diagnoses, driving demand for medications. As the region faces a
rising burden of chronic diseases, including cardiovascular conditions, there
is a greater emphasis on long-term management of IHD, fueling the need for
continuous and effective treatments, such as statins, anti-anginal drugs, and
newer therapies. These combined factors position the Asia-Pacific region as the
fastest-growing market for IHD drugs, with continued growth expected as
healthcare needs evolve.
Major companies operating in Global Ischemic Heart Disease (IHD) Drugs Market are:
- Bayer AG
- Eli Lilly and
Company
- Novartis
International AG
- Pfizer, Inc.
- Sanofi S.A.
- Actelion
Pharmaceuticals Ltd.
- Baxter
International Inc.
- Boehringer
Ingelheim International GmbH
- Bristol-Myers
Squibb Company
- F. Hoffmann-La
Roche AG
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The global Ischemic Heart Disease (IHD) drugs market
is evolving as both treatment options and patient demographics shift. The
increasing focus on cost-effective, long-term therapies is driving the
development of combination drugs that address multiple risk factors
simultaneously. As chronic diseases become more prevalent due to urbanization
and lifestyle changes, the market is seeing greater demand for medications that
offer not just symptomatic relief but also disease-modifying effects. The
growing integration of digital health solutions and telemedicine is further
transforming patient care, enhancing adherence to IHD treatments. With these
trends, the IHD drug market is poised for sustained growth, especially as
patient-centric solutions gain momentum across regions”, said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“Ischemic Heart Disease (IHD) Drugs Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease
Class (Angina Pectoris, Myocardial Infarction), By Drug Class
(Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE
Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Region and
Competition, 2020-2030F”, has evaluated
the future growth potential of Global Ischemic Heart Disease (IHD) Drugs Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Ischemic Heart Disease (IHD) Drugs Market.
Contact
TechSci Research
LLC
420 Lexington
Avenue, Suite 300,
New York, United
States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com